Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HGFAC | Q04756 | 2/20 | 0.58 |
| ▸ | HPN | P05981 | 1/20 | 0.58 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.58 |
| ▸ | F7 | P08709 | 18/20 | 0.50 |
| ▸ | F3 | P13726 | 13/20 | 0.50 |
| ▸ | F10 | P00742 | 16/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 15/20 | 0.47 |
| ▸ | F2 | P00734 | 13/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 11/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 11/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14458651 | 0.91 | HGFAC (0.61) | HGFACHPNST14F7F3 | |
| SCHEMBL14458635 | 0.91 | HGFAC (0.61) | HGFACHPNST14F7F3 | |
| SCHEMBL14458650 | 0.91 | HGFAC (0.61) | HGFACHPNST14F7F3 | |
| SCHEMBL8295428 | 0.89 | HGFAC (0.70) | HGFACHPNST14F7F3 | |
| SCHEMBL14458636 | 0.85 | HGFAC (0.58) | HGFACHPNST14F7F3 | |
| SCHEMBL14458639 | 0.84 | HGFAC (0.43) | HGFACHPNST14F7F3 | |
| SCHEMBL8299408 | 0.83 | F7 (0.66) | F7F3F10PRSS1F2 | |
| SCHEMBL14458637 | 0.81 | F7 (0.48) | HGFACHPNST14F7F3 | |
| SCHEMBL14415864 | 0.79 | HGFAC (0.73) | HGFACHPNST14F7F3 | |
| SCHEMBL8295963 | 0.79 | HGFAC (0.73) | HGFACHPNST14F7F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7250447-B2 | Acylsulfamide inhibitors of factor VIIa | GENENTECH, INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250447-B2 | Acylsulfamide inhibitors of factor VIIa | GENENTECH, INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-20070037814-A1 | ACYLSULFAMIDE INHIBITORS OF FACTOR VIIa | GENENTECH, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037814-A1 | ACYLSULFAMIDE INHIBITORS OF FACTOR VIIa | GENENTECH, INC. (US) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037814-A1 | ACYLSULFAMIDE INHIBITORS OF FACTOR VIIa | TFPI, HABP2, TFPI2 | HGFAC 188/4885HPN 44/4885ST14 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.